|
|
Prepublished online as a Blood First Edition Paper on October 17, 2002; DOI 10.1182/blood-2002-07-2337.
Previous Article | Table of Contents | Next Article 
Blood, 15 February 2003, Vol. 101, No. 4, pp. 1551-1557
NEOPLASIA
Transcriptional regulation of the cystathionine- -synthase gene
in Down syndrome and non-Down syndrome megakaryocytic leukemia cell
lines
Yubin Ge,
Tanya L. Jensen,
Larry H. Matherly, and
Jeffrey W. Taub
From the Experimental and Clinical Therapeutics
Program, Barbara Ann Karmanos Cancer Institute, Division of Pediatric
Hematology/Oncology, Children's Hospital of Michigan, and the
Departments of Pharmacology and Pediatrics, Wayne State University
School of Medicine, Detroit, MI.
Children with Down syndrome (DS) with acute myeloid leukemia (AML)
have significantly higher event-free survival rates compared to those
with non-DS AML, linked to greater cytosine arabinoside (ara-C)
sensitivity and higher transcript levels of the chromosome 21-localized gene, cystathionine- -synthase
(CBS), in DS myeloblasts. In this study, we
examined the transcriptional regulation of the CBS gene in
the DS megakaryocytic leukemia (AMkL) cell line, CMK, characterized by
significantly higher CBS transcripts compared with the
non-DS AMkL cell line, CMS. Rapid amplification of 5'-cDNA ends
(5'-RACE) analysis demonstrated exclusive use of the CBS 1b promoter in the cell lines, and transient transfections
with the full-length CBS 1b luciferase reporter gene
construct showed 40-fold greater promoter activity in the CMK than CMS
cells. Electrophoretic mobility shift assays showed enhanced binding of
the transcription factors Sp1/Sp3 to 2 GC/GT-box elements (GC-f and
GT-d) in the upstream regions of the CBS 1b promoter in CMK nuclear
extracts and undetectable binding in CMS cells. Mutation of the GC-f-
or GT-d-binding site resulted in an approximately 90% decrease of the
CBS 1b promoter activity in transient transfections of
CMK cells. Chromatin immunoprecipitation assays confirmed in vivo binding of Sp3, USF-1, and nuclear factor YA (NF-YA) to the
CBS 1b promoter region in chromatin extracts of CMK and
CMS cells. Decreased binding of Sp1/Sp3 in CMK nuclear extracts
following treatment with calf alkaline phosphatase suggested a role for phosphorylation of Sp1/Sp3 in regulating CBS promoter
activity and in the differential CBS expression between CMK
and CMS cells. The results of this study with clinically relevant cell
line models suggest potential mechanisms for disparate patterns of
CBS gene expression in DS and non-DS myeloblasts and may,
in part, explain the greater sensitivity to chemotherapy shown by
patients with DS AML.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. Edwards, C. Xie, K. M. LaFiura, A. A. Dombkowski, S. A. Buck, J. L. Boerner, J. W. Taub, L. H. Matherly, and Y. Ge
RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia
Blood,
September 24, 2009;
114(13):
2744 - 2752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Y. C. Wu, R. Wu, Y. Chen, N. Tarasova, and M. M. J. Chang
PMA Stimulates MUC5B Gene Expression through an Sp1-Based Mechanism in Airway Epithelial Cells
Am. J. Respir. Cell Mol. Biol.,
November 1, 2007;
37(5):
589 - 597.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ge, A. A. Dombkowski, K. M. LaFiura, D. Tatman, R. S. Yedidi, M. L. Stout, S. A. Buck, G. Massey, D. L. Becton, H. J. Weinstein, et al.
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia
Blood,
February 15, 2006;
107(4):
1570 - 1581.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. N. Maclean, E. Kraus, and J. P. Kraus
The Dominant Role of Sp1 in Regulating the Cystathionine {beta}-Synthase -1a and -1b Promoters Facilitates Potential Tissue-specific Regulation by Kruppel-like Factors
J. Biol. Chem.,
March 5, 2004;
279(10):
8558 - 8566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ge, T. L. Jensen, M. L. Stout, R. M. Flatley, P. J. Grohar, Y. Ravindranath, L. H. Matherly, and J. W. Taub
The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell Lines
Cancer Res.,
January 15, 2004;
64(2):
728 - 735.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gurbuxani, P. Vyas, and J. D. Crispino
Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome
Blood,
January 15, 2004;
103(2):
399 - 406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Gilliland, C. T. Jordan, and C. A. Felix
The Molecular Basis of Leukemia
Hematology,
January 1, 2004;
2004(1):
80 - 97.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ge, T. L. Jensen, L. H. Matherly, and J. W. Taub
Physical and Functional Interactions between USF and Sp1 Proteins Regulate Human Deoxycytidine Kinase Promoter Activity
J. Biol. Chem.,
December 12, 2003;
278(50):
49901 - 49910.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|